• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

    5/8/25 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range.

    Executive Summary

    Q1 2025 vs. Prior-year Quarter

    Revenue

    $364.5 million; (12.7)%

    • (3.0)% FX impact or $(12.3) million

    Earnings Per Share

    (EPS)

    $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges

    Customers

    776,712; (11)%

    Paid Affiliates

    131,518; (15)%

    Sales Leaders

    31,036; (20)%

    "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove year-over-year growth in Latin America and our Rhyz manufacturing segment, but we continue to experience consumer caution in premium beauty due to concerns such as inflation and tariffs in many parts of the world. Through 2025, we remain focused on building on our recent product launches and preparing for the preview of our Prysm iO intelligent wellness device in the back half of the year. This palm-sized device provides real-time insights into a customer's health, informing recommendations for product subscriptions and increasing customer satisfaction and loyalty. We are also laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026 and prioritizing our efforts to continue improving margins across the board."

    Q1 2025 Year-over-year Operating Results

    Revenue

    $364.5 million compared to $417.3 million

    • (3.0)% FX impact or $(12.3) million

    Gross Margin

    67.8% compared to 70.5%

    • Nu Skin business was 76.7% compared to 76.9%

    Selling Expenses

    32.5% compared to 36.8%

    • Nu Skin business was 38.7% compared to 41.7%

    G&A Expenses

    31.1% or 28.9% excluding certain charges compared to 29.9%

    Restructuring and

    Impairment Expenses

    $25.1 million impairment compared to $7.3 million restructuring charges

    Operating Margin

    (2.7)% or 6.4% excluding impairment and other charges compared to 2.1% or 3.8% excluding restructuring charges

    Interest Expense

    $3.3 million compared to $7.3 million

    Gain on Sale of

    Business

    $176.2 million gain on sale of Mavely

    Other Expense

    $28.4 million compared to $0.4 million

    • Reflects $28.1 million unrealized loss on investment

    Income Tax Rate

    20.1% or 41.9% excluding Mavely gain and other charges compared to 148.4% or 48.5% excluding restructuring charges

    EPS

    $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges

    Stockholder Value

    Dividend Payments

    $3.0 million

    Stock Repurchases

    $5.0 million

    • $157.4 million remaining in authorization

    Q2 and Full-year 2025 Outlook

    Q2 2025 Revenue

    $355 to $390 million; (19)% to (11)% or (17)% to (9)% excluding Mavely 2024 revenue

    • Approximately (3) to (2)% FX impact

    Q2 2025 EPS

    $0.20 to $0.30

    2025 Revenue

    $1.48 to $1.62 billion; (15)% to (6)% or (11)% to (3)% excluding Mavely 2024 revenue

    • Approximately (3)% FX impact

    2025 EPS

    $2.80 to $3.20 or $0.90 to $1.30 excluding Mavely gain and other charges

    "In addition to delivering on revenue and adjusted earnings, we saw encouraging improvement in core Nu Skin operating margin, driven by ongoing cost efficiency initiatives across every segment," said James D. Thomas, chief financial officer. "We also made meaningful progress in strengthening our balance sheet by reducing outstanding debt by $155 million, achieving our lowest debt level in more than 10 years. In addition, we returned $8 million to shareholders — $3 million in the form of dividends and $5 million via share repurchases. While macroeconomic uncertainty around trade tensions and tariffs continues to impact visibility, we are maintaining our adjusted annual guidance as we closely monitor developments throughout the remainder of 2025. For the second quarter, we project revenue between $355 million and $390 million, with earnings per share in the range of $0.20 to $0.30."

    Conference Call

    The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 22, 2025.

    About Nu Skin Enterprises Inc.

    The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

    Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the macro environment and the company's performance, growth and growth opportunities, shareholder value, product previews and launches, investments, initiatives, and new market expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "accelerate," "project," "vision," "remain," "continue," "outlook," "guidance," "improve," "will," "would," "could," "may," "might," the negative of these words and other similar words.

    The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

    • any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
    • risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
    • economic conditions and events globally;
    • the company's future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets;
    • competitive pressures in the company's markets;
    • risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
    • adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
    • political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
    • uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
    • risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
    • uncertainties regarding the future financial performance of the businesses the company has acquired;
    • risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
    • regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.

    The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

    Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

    Earnings per share, general & administrative expenses, operating margin and income tax rate, each excluding the gain from the Mavely sale, restructuring charges, impairment charges, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures.

    • Restructuring charges and impairment charges are not part of the ongoing operations of our underlying business;
    • Mavely revenue is no longer included in our operations following our sale of this business on January 2, 2025; and
    • the gain from the Mavely sale and the other charges incurred in connection with this sale that have been excluded in the non-GAAP financial measures are not typical for our ongoing operations.

    The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share, general & administrative expenses, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

    The following table sets forth revenue for the three-month periods ended March 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):

    Three Months Ended

    March 31,

     

     

    Constant-

    Currency

     

    2025

     

    2024

     

    Change

     

    Change

    Nu Skin

    Americas

    $

    69,058

     

    $

    75,031

     

     

    (8.0)%

     

     

    (1.3)%

    Southeast Asia/Pacific

     

    52,172

     

     

    60,065

     

     

    (13.1)%

     

     

    (12.0)%

    Mainland China

    47,775

     

    61,067

     

     

    (21.8)%

     

     

    (20.6)%

    Japan

     

    42,765

     

     

    44,236

     

     

    (3.3)%

     

     

    (0.8)%

    Europe & Africa

     

    33,021

     

     

    42,273

     

     

    (21.9)%

     

     

    (19.5)%

    South Korea

     

    32,515

     

     

    40,963

     

     

    (20.6)%

     

     

    (13.3)%

    Hong Kong/Taiwan

     

    28,447

     

     

    30,466

     

     

    (6.6)%

     

     

    (4.0)%

    Other

     

    529

     

     

    672

     

     

    (21.3)%

     

     

    (21.3)%

    Total Nu Skin

    306,282

    354,773

    (13.7)%

    (10.2)%

    Rhyz

    Manufacturing

    55,290

    50,302

    9.9%

    9.9%

    Rhyz other

    2,918

    12,231

    (76.1)%

    (76.1)%

    Total Rhyz

    58,208

    62,533

    (6.9)%

    (6.9)%

    Total

    $

    364,490

     

    $

    417,306

     

     

    (12.7)%

     

     

    (9.7)%

    The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2025, and 2024:

    Three Months Ended

    March 31,

    2025

     

    2024

    Change

    Customers

    Americas

    227,514

    199,399

    14%

    Southeast Asia/Pacific

     

    74,584

    93,411

    (20)%

    Mainland China

    122,474

    162,239

    (25)%

    Japan

     

    107,742

    108,808

    (1)%

    Europe & Africa

     

    130,154

    163,481

    (20)%

    South Korea

     

    71,721

    100,230

    (28)%

    Hong Kong/Taiwan

     

    42,523

    47,693

    (11)%

    Total Customers

    776,712

    875,261

    (11)%

     

    Paid Affiliates

    Americas

     

    26,936

    29,081

    (7)%

    Southeast Asia/Pacific

     

    22,296

    29,778

    (25)%

    Mainland China

    19,859

    24,405

    (19)%

    Japan

     

    21,073

    21,679

    (3)%

    Europe & Africa

     

    15,184

    18,313

    (17)%

    South Korea

     

    16,548

    20,594

    (20)%

    Hong Kong/Taiwan

     

    9,622

    10,321

    (7)%

    Total Paid Affiliates

    131,518

    154,171

    (15)%

     

    Sales Leaders

    Americas

     

    6,174

    6,616

    (7)%

    Southeast Asia/Pacific

     

    4,542

    5,570

    (18)%

    Mainland China

    6,214

    9,600

    (35)%

    Japan

     

    6,210

    6,385

    (3)%

    Europe & Africa

     

    2,839

    3,715

    (24)%

    South Korea

     

    2,850

    4,122

    (31)%

    Hong Kong/Taiwan

     

    2,207

    2,601

    (15)%

    Total Sales Leaders

    31,036

    38,609

    (20)%

    • "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
    • "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks.
    • "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

    NU SKIN ENTERPRISES, INC.

    Consolidated Statements of Income (Unaudited)

    (U.S. dollars in thousands, except per share amounts)

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

    Revenue

    $

    364,490

     

    $

    417,306

    Cost of sales

     

    117,529

     

     

    123,242

    Gross profit

     

    246,961

     

     

    294,064

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

    Selling expenses

     

    118,546

     

     

    153,542

    General and administrative expenses

     

    113,204

     

     

    124,566

    Restructuring and impairment expenses

    25,114

    7,134

    Total operating expenses

     

    256,864

     

     

    285,242

     

     

     

     

     

     

    Operating income (loss)

     

    (9,903)

     

     

    8,822

    Interest expense

    3,283

    7,325

    Gain on sale of business

     

    176,162

     

     

    —

    Other expense, net

     

    (28,375)

     

     

    (396)

     

     

     

     

     

     

    Income before provision for income taxes

     

    134,601

     

     

    1,101

    Provision for income taxes

     

    27,086

     

     

    1,634

     

     

     

     

     

     

    Net income (loss)

    $

    107,515

     

    $

    (533)

     

     

     

     

     

     

    Net income (loss) per share:

     

     

     

     

     

    Basic

    $

    2.16

     

    $

    (0.01)

    Diluted

    $

    2.14

     

    $

    (0.01)

     

     

     

     

     

     

    Weighted-average common shares outstanding (000s):

     

     

     

     

     

    Basic

     

    49,764

     

     

    49,538

    Diluted

     

    50,328

     

     

    49,538

     

    NU SKIN ENTERPRISES, INC.

    Consolidated Balance Sheets (Unaudited)

    (U.S. dollars in thousands)

     

    March 31,

    2025

     

    December 31,

    2024

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    203,770

     

    $

    186,883

    Current investments

     

    9,781

     

     

    11,111

    Accounts receivable, net

     

    56,576

     

     

    50,784

    Inventories, net

     

    188,776

     

     

    190,242

    Prepaid expenses and other

    65,954

    72,643

    Current assets held for sale

     

    —

     

     

    26,936

    Total current assets

     

    524,857

     

     

    538,599

     

     

     

     

     

     

    Property and equipment, net

     

    380,067

     

     

    379,595

    Operating lease right-of-use assets

    79,389

    72,605

    Goodwill

     

    83,625

     

     

    83,625

    Other intangible assets, net

     

    47,554

     

     

    74,278

    Other assets

    275,919

    298,008

    Long-term assets held for sale

     

    —

     

     

    22,204

    Total assets

    $

    1,391,411

     

    $

    1,468,914

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

    Accounts payable

    $

    33,590

     

    $

    34,880

    Accrued expenses

     

    206,710

     

     

    217,808

    Current portion of long-term debt

    20,000

    30,000

    Current liabilities held for sale

     

    —

     

     

    13,919

    Total current liabilities

     

    260,300

     

     

    296,607

     

    Operating lease liabilities

     

    61,949

     

     

    58,439

    Long-term debt

     

    218,757

     

     

    363,613

    Other liabilities

    96,436

    97,475

    Long-term liabilities held for sale

     

    —

     

     

    1,325

    Total liabilities

     

    637,442

     

     

    817,459

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

    Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued

     

    91

     

     

    91

    Additional paid-in capital

     

    623,477

     

     

    627,787

    Treasury stock, at cost – 41.2 million and 40.8 million shares

     

    (1,562,211)

     

     

    (1,563,614)

    Accumulated other comprehensive loss

     

    (123,850)

     

     

    (124,758)

    Retained earnings

     

    1,8416,462

     

     

    1,711,949

    Total stockholders' equity

     

    753,969

     

     

    651,455

    Total liabilities and stockholders' equity

    $

    1,391,411

     

    $

    1,468,914

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of General and Administrative Expenses Excluding Certain Charges to GAAP General and Administrative Expenses

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2025

     

    2024

    General and administrative expenses

     

    $

    113,204

     

    $

    124,566

    Impact of other charges(1)

     

     

    (7,966)

     

     

    -

    Adjusted general and administrative expenses

     

    $

    105,238

     

    $

    124,566

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    General and administrative expenses as a percentage of revenue

     

     

    31.1%

     

     

    29.9%

    General and administrative expenses as a percentage of revenue, excluding certain charges

     

     

    28.9%

     

     

    29.9%

     

     

     

     

     

     

     

    Revenue

     

    $

    364,490

     

    $

    417,306

    __________________________

    (1) Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2025

     

    2024

    Operating Income (loss)

     

    $

    (9,903)

     

    $

    8,822

    Impact of other charges(1)

     

     

    7,966

     

     

    -

    Impact of restructuring and impairment

     

     

    25,114

     

     

    7,134

    Adjusted operating income

     

    $

    23,177

     

    $

    15,956

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin

     

     

    (2.7)%

     

     

    2.1%

    Operating margin, excluding certain charges

     

     

    6.4%

     

     

    3.8%

     

     

     

     

     

     

     

    Revenue

     

    $

    364,490

     

    $

    417,306

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Effective Tax Rate Excluding Impact of Mavely Gain and Certain Charges to GAAP Effective Tax Rate

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2025

     

    2024

    Provision for income taxes

     

    $

    27,086

     

    $

    1,634

    Impact of other charges(1) on provision for income taxes

     

     

    725

     

     

    -

    Impact of restructuring and impairment on provision for income taxes

     

     

    5,433

     

     

    2,356

    Impact of gain on Mavely sale on provision for income taxes

     

     

    (31,104)

     

     

     

    Impact of unrealized investment loss on provision for income taxes

     

     

    6,074

     

     

    -

    Provision for income taxes, excluding impact of Mavely gain and certain charges

    $

    8,214

    $

    3,990

     

     

     

     

     

     

     

    Income before provision for income taxes

     

     

    134,601

     

     

    1,101

    Impact of other charges(1)

     

     

    7,966

     

     

    -

    Impact of restructuring and impairment expense:

     

     

    25,114

     

     

    7,134

    Impact of gain on Mavely sale

     

     

    (176,162)

     

     

    -

    Impact of unrealized investment loss

     

     

    28,077

     

     

    -

    Income before provision for income taxes, excluding impact of certain charges

    $

    19,596

    $

    8,235

     

     

     

     

     

     

     

    Effective tax rate

     

     

    20.1%

     

     

    148.4%

    Effective tax rate, excluding impact of certain charges

     

     

    41.9%

     

     

    48.5%

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

    2025

     

    2024

    Net income (loss)

     

    $

    107,515

     

    $

    (533)

    Impact of other charges

     

     

     

     

     

     

    Other charges(1)

     

     

    7,966

     

     

    -

    Tax impact

     

     

    (725)

     

     

    -

    Impact of restructuring and impairment expense:

     

     

     

     

     

     

    Restructuring and impairment

     

     

    25,114

     

     

    7,134

    Tax impact

     

     

    (5,433)

     

     

    (2,356)

    Impact of gain on Mavely sale

     

     

     

     

     

     

    Gain on Mavely sale

     

     

    (176,162)

     

     

    -

    Tax impact

     

     

    31,104

     

     

    -

    Impact of unrealized investment loss

     

     

     

     

     

     

    Unrealized investment loss

     

     

    28,077

     

     

    -

    Tax impact

     

     

    (6,074)

     

     

    -

    Adjusted net income

     

    $

    11,382

     

    $

    4,245

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share

     

    $

    2.14

     

    $

    (0.01)

    Diluted earnings per share, excluding restructuring impact

     

    $

    0.23

     

    $

    0.09

     

     

     

     

     

     

     

    Weighted-average common shares outstanding (000)

     

     

    50,328

     

     

    49,538

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share

     

     

     

     

     

     

     

     

     

    Year ended December 31, 2025

     

     

    Low end

    High end

    Earnings Per Share

     

    $

    2.80

     

    $

    3.20

    Impact of other charges

     

     

     

     

     

     

    Other charges(1)

     

     

    0.16

     

     

    0.16

    Tax impact

     

     

    (0.01)

     

     

    (0.01)

    Impact of restructuring and impairment expense:

     

     

     

     

     

     

    Restructuring and impairment

     

     

    0.50

     

     

    0.50

    Tax impact

     

     

    (0.11)

     

     

    (0.11)

    Impact of gain on Mavely sale

     

     

     

     

     

     

    Gain on Mavely sale

     

     

    (3.50)

     

     

    (3.50)

    Tax impact

     

     

    0.62

     

     

    0.62

    Impact of unrealized investment loss

     

     

     

     

     

     

    Unrealized investment loss

     

     

    0.56

     

     

    0.56

    Tax impact

     

     

    (0.12)

     

     

    (0.12)

    Adjusted EPS

     

    $

    0.90

     

    $

    1.30

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Revenue Growth Rates Excluding Mavely to GAAP Revenue Growth Rates

    (in thousands)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three months ended

    June 30, 2025

     

    Year ended

    December 31, 2025

     

     

    Low end

     

    High end

     

    Low end

     

    High end

    2024 Revenue

     

    $

    439,081

     

    $

    439,081

     

    $

    1,732,084

     

    $

    1,732,084

    Less: Mavely 2024 Revenue

     

     

    12,007

     

     

    12,007

     

     

    69,620

     

     

    69,620

    Adjusted 2024 Revenue

     

    $

    427,074

     

    $

    427,074

     

    $

    1,662,464

     

    $

    1,662,464

     

     

     

     

     

     

     

     

     

     

     

     

     

    Revenue Growth Rate

     

     

    (19)%

     

     

    (11)%

     

     

    (15)%

     

     

    (6)%

    Revenue Growth Rate, excluding Mavely

     

     

    (17)%

     

     

    (9)%

     

     

    (11)%

     

     

    (3)%

     

     

     

     

     

     

     

     

     

     

     

     

     

    2025 Forecasted Revenue

     

    $

    355,000

     

    $

    390,000

     

    $

    1,480,000

     

    $

    1,620,000

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508826996/en/

    Media: [email protected], (801) 345-6397

    Investors: [email protected], (801) 345-3577

    Get the next $NUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce First Quarter 2025 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 22. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of

      4/2/25 4:15:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, President of Global Sales Keisel Justin S increased direct ownership by 0.19% to 90,922 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      3/24/25 6:06:31 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Woodbury Edwina D was granted 12 shares, increasing direct ownership by 0.04% to 29,471 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      3/6/25 7:27:39 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • EVP, President of Global Sales Keisel Justin S was granted 51,747 shares, increasing direct ownership by 133% to 90,749 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      2/27/25 4:48:55 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Financials

    Live finance-specific insights

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce First Quarter 2025 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 22. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of

      4/2/25 4:15:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nu Skin downgraded by Jefferies with a new price target

      Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

      1/31/23 6:17:27 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

      DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

      2/17/22 4:46:52 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

      Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

      11/24/21 11:03:39 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nu Skin Enterprises Inc.

      10-Q - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/8/25 8:52:03 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/8/25 4:16:05 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nu Skin Enterprises Inc.

      SCHEDULE 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      4/17/25 9:35:30 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/12/24 4:47:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/6/24 10:20:59 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/4/24 10:21:31 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

      Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

      9/12/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nu Skin Sets New GUINNESS WORLD RECORDS™ Title for the Most People Packing Meal Kits in 24 Hours

      To celebrate the company's 40th anniversary, sales leaders, employees and local partners packed more than 550,000 meals for children throughout the United States Nu Skin Enterprises, Inc. (NYSE:NUS), a global leader in beauty and wellness, today announced a new GUINNESS WORLD RECORDS title for the Most People Packing Meal Kits in 24 Hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729413403/en/Nu Skin Sets New GUINNESS WORLD RECORDS™ Title for the Most People Packing Meal Kits in 24 Hours (Graphic: Business Wire) Nu Skin hosted a service event at the Salt Palace Convention Center in Salt Lake City where 2,196 people ac

      7/29/24 8:00:00 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care